By Sabela Ojea


Invivyd said it expects net product revenue of $150 million to $200 million this year from its Covid-19 preventive treatment, shortly after receiving an emergency use authorization from the Food and Drug Administration.

The biotechnology company on Thursday said that based on expected net product revenue on the treatment for the year, it also expects to end 2024 with at least $55 million in cash and cash equivalents.

The pre-Covid-19 exposure injection Pemgarda is now commercially available for purchase across the U.S.

On March 22, Invivyd said the FDA granted the emergency use authorization to its Pemgarda monoclonal antibody to prevent Covid-19 in immunocompromised adolescents and adults.


Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix


(END) Dow Jones Newswires

04-04-24 1638ET